Compare Stocks

→ Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZRX AzurRx BioPharma	$2.73 -9.6%	$4.04	$3.36 ▼ $26.30	$25.46M	1.51	628,703 shs	45,267 shs
ETST Earth Science Tech	$0.06	$0.07	$0.00 ▼ $0.12	$18.29M	1.77	66,422 shs	26,350 shs
EVOK Evoke Pharma	$0.47 +7.2%	$0.60	$0.42 ▼ $2.40	$3.96M	0.22	53,158 shs	3,834 shs
KMPH Zevra Therapeutics		$5.51	$4.00 ▼ $6.92	$200.47M	2.16	189,500 shs	64,100 shs
KZIA Kazia Therapeutics	$0.37 -0.1%	$0.31	$0.19 ▼ $1.41	$6.04M	2.12	725,611 shs	36,768 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZRX AzurRx BioPharma	-3.21%	+6.34%	-23.93%	-38.99%	+5.96%
ETST Earth Science Tech	0.00%	-13.24%	-10.61%	-26.25%	+84.38%
EVOK Evoke Pharma	-2.57%	-8.94%	-27.90%	-33.44%	-76.93%
KMPH Zevra Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
KZIA Kazia Therapeutics	-6.22%	+5.37%	+15.59%	+7.29%	-72.98%

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KMPH Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A
KMPH Zevra Therapeutics	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	($0.76) per share	N/A
ETST Earth Science Tech	$50K	365.78	N/A	N/A	N/A	∞
EVOK Evoke Pharma	$5.18M	0.76	N/A	N/A	($0.77) per share	-0.61
KMPH Zevra Therapeutics	$10.72M	0.00	N/A	23.28	$3.63 per share	0.00
KZIA Kazia Therapeutics	$20K	302.13	N/A	N/A	$0.50 per share	0.74

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZRX AzurRx BioPharma	-$32.67M	-$11.50	N/A	N/A	N/A	N/A	-482.96%	-258.47%	N/A
ETST Earth Science Tech	-$370K	N/A	0.00	∞	N/A	5.77%	20.61%	11.73%	N/A
EVOK Evoke Pharma	-$7.79M	-$2.33	N/A	∞	N/A	-150.43%	-517.99%	-91.83%	5/20/2024 (Estimated)
KMPH Zevra Therapeutics	-$8.56M	N/A	0.00	N/A	N/A	-328.56%	-16.12%	-14.17%	N/A
KZIA Kazia Therapeutics	-$13.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest EVOK, KMPH, ETST, KZIA, and AZRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/14/2024	Q4 2023	EVOK Evoke Pharma	N/A	-$0.59	-$0.59	-$0.59	N/A	$1.68 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZRX AzurRx BioPharma	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
KMPH Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A
KZIA Kazia Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZRX AzurRx BioPharma	N/A	1.33	1.33
ETST Earth Science Tech	0.10	0.87	0.39
EVOK Evoke Pharma	N/A	2.25	2.09
KMPH Zevra Therapeutics	0.14	10.10	10.10
KZIA Kazia Therapeutics	N/A	0.71	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
AZRX AzurRx BioPharma	6.27%
ETST Earth Science Tech	N/A
EVOK Evoke Pharma	N/A
KMPH Zevra Therapeutics	19.39%
KZIA Kazia Therapeutics	30.89%

Insider Ownership

Company	Insider Ownership
AZRX AzurRx BioPharma	7.30%
ETST Earth Science Tech	24.90%
EVOK Evoke Pharma	11.78%
KMPH Zevra Therapeutics	1.10%
KZIA Kazia Therapeutics	1.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AZRX AzurRx BioPharma	12	9.33 million	8.65 million	Not Optionable
ETST Earth Science Tech	8	309.98 million	232.80 million	Not Optionable
EVOK Evoke Pharma	4	8.48 million	7.48 million	Not Optionable
KMPH Zevra Therapeutics	22	34.51 million	34.13 million	Optionable
KZIA Kazia Therapeutics	2,021	16.34 million	16.18 million	Optionable

EVOK, KMPH, ETST, KZIA, and AZRX Headlines

Source	Headline
	Kazia Therapeutics Limited (NASDAQ:KZIA) Sees Significant Increase in Short Interest americanbankingnews.com - April 16 at 1:26 AM
	Kazia licenses rare epilepsy drug paxalisib to Korea’s Sovargen bioworld.com - March 23 at 12:04 PM
	Kazia Therapeutics Ltd ADR KZIA morningstar.com - March 20 at 4:52 PM
	KZIA Apr 2024 2.500 call finance.yahoo.com - March 16 at 12:37 AM
	Kazia announces presentation of new data at AACR Annual Meeting prnewswire.com - March 13 at 8:00 AM
	What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday? msn.com - February 21 at 6:59 PM
	Kazia Therapeutics Limited: Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint finanznachrichten.de - February 21 at 1:58 PM
	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint finance.yahoo.com - February 21 at 8:58 AM
	Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint prnewswire.com - February 21 at 7:30 AM
	Kazia Therapeutics Limited thestreet.com - February 19 at 6:40 PM
	Kazia Therapeutics Ltd. ADR wsj.com - February 14 at 7:28 PM
	Viking Therapeutics, Inc. Common Stock (VKTX) nasdaq.com - February 13 at 3:25 AM
	KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS finance.yahoo.com - January 18 at 9:40 AM
	Kazia Therapeutics files to sell 591,697 ADSs for holders msn.com - December 15 at 10:44 PM
	Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering finance.yahoo.com - December 5 at 11:06 PM
	Kazia Therapeutics Shares Tumble on $2 Million Direct Offering marketwatch.com - December 1 at 9:29 AM
	Kazia Therapeutics Announces Registered Direct Offering - Quick Facts markets.businessinsider.com - December 1 at 9:29 AM
	Kazia Therapeutics Announces $2 Million Registered Direct Offering finance.yahoo.com - December 1 at 9:29 AM
	Kazia Therapeutics Enters Non-binding LOI For Paxalisib Rights Outside Of Oncology markets.businessinsider.com - November 29 at 1:55 PM
	Kazia stock jumps after proposed license deal for paxalisib outside oncology msn.com - November 29 at 1:55 PM
	Kazia Therapeutics Signs Letter of Intent for Paxalisib Development, Commercialization marketwatch.com - November 29 at 7:53 AM
	KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY finance.yahoo.com - November 29 at 7:53 AM
	KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING finance.yahoo.com - November 21 at 8:56 AM
	Kazia Therapeutics gets deficiency notice from Nasdaq msn.com - November 20 at 7:08 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

AzurRx BioPharma

NASDAQ:AZRX

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Earth Science Tech

OTCMKTS:ETST

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

Evoke Pharma

NASDAQ:EVOK

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Zevra Therapeutics

NASDAQ:KMPH

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Kazia Therapeutics

NASDAQ:KZIA

Kazia Therapeutics Limited operates as a biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma, diffuse intrinsic pontine glioma/advanced solid tumors, atypical teratoid rhabdoid tumor, brain metastases, triple negative breast cancer, and primary central nervous system lymphoma. It is also developing EVT801, a small molecule targeted therapeutic vascular endothelial growth factor receptor 3 inhibitor. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial